X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XFOR 12.03.2024

Full Press ReleaseSEC FilingsOur XFOR Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand
  • 12.04.2024 - X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & Exposition
  • 12.03.2024 - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

  • 01.16.2025 - S-8 Securities to be offered to employees in employee benefit plans
  • 01.13.2025 - 8-K Current report
  • 01.13.2025 - EX-99.1 EX-99.1

BOSTON,Dec. 03, 2024(GLOBE NEWSWIRE) --X4 Pharmaceuticals(Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective onDecember 2, 2024, the company issued inducement awards to new employees under theX4 Pharmaceuticals, Inc.2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 396,824 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.

The options have a ten-year term and an exercise price of$0.371per share, which is equal to the closing price of X4’s common stock onDecember 2, 2024. Each option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employee’s continued employment with X4 on such vesting dates. The options are subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of an award agreement covering the grant.

AboutX4 PharmaceuticalsX4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has receivedU.S.approval as XOLREMDI® (mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are inBoston, Massachusettsand our research center of excellence is inVienna, Austria. For more information, please visit our website atwww.x4pharma.com.

Company Contact:José JuvesHead of Corporate & Patient Affairsjose.juves@x4pharma.com

Investor Contact:Daniel FerryManaging Director,LifeSci Advisorsdaniel@lifesciadvisors.com(617) 430-7576

Primary Logo

Source: X4 Pharmaceuticals

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com